Eitan Medical opens a new manufacturing facility

[ad_1]

Eitan Medical, a business continuum of infusion therapy and drug delivery, has opened its new manufacturing facility at the company’s headquarters. On-site manufacturing will support Eitan Medicals’ production scale of its Pharmaceutical Solutions division.

The facility will produce the Sorrel wearable drug delivery platform on multiple device configurations, including wearable injectors based on Sorrel vials and cartridges, prefilled and prefilled in primary containers up to 50mL, as well as small volume body injectors.

Oded Peres, vice president of operations at Eitan Medical, said: Having on-site manufacturing capabilities allows for close alignment between our R&D, engineering, quality and manufacturing teams and gives us the agility to rapidly deploy innovations and new features. of product. With multiple cleanrooms, production lines and automated test stations, we can provide quality assurance for every device that passes through our lines.

The new facility comprises 410 square meters (4413 square feet) with two ISO-7 cleanrooms, as well as 50 square meters (538 square feet) of support areas. Two semi-automated production lines incorporate both fully and semi-automated technologies and processes, including ultrasonic machines, duckbill dispensing robots, high-end pressure and leak testers, automated visual inspection heat staking stations, and functional testers with visual inspection of the needle with high resolution and lubrication of the needle. The increased manufacturing capacity of Sorrel devices will support Eitan Medicals’ pharmaceutical partners working on feasibility projects, joint development and clinical trials, as well as commercial implementation. The facility also has manual production lines to support Eitan Medicals’ growing customer demand and allows for multiple products and customer lines to be produced concurrently.

Dr. Andrei Yosef, General Manager Pharmaceutical Solutions at Eitan Medical, said: The production lines significantly enhance our ability to support customers and meet growing market demand, while maintaining full control and quality of our devices. We have several pharmaceutical partners looking to utilize our Sorrel wearable drug delivery platform and our increased manufacturing capacity will allow us to meet this growing demand.

[ad_2]